| Susan L Urben, MD | |
|
330 S Garden Way, Ste 300, Eugene, OR 97401-8176 | |
| (541) 334-3370 | |
| (541) 334-3372 |
| Full Name | Susan L Urben |
|---|---|
| Gender | Female |
| Speciality | Otolaryngology |
| Experience | 32 Years |
| Location | 330 S Garden Way, Eugene, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1316925829 | NPI | - | NPPES |
| 151200 | Medicaid | OR |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD21483 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sacred Heart Medical Center - Riverbend | Springfield, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Healthcare Resources Llc | 4486835477 | 129 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.
McMaster scientists are very close to defining small molecule drugs that should be able to redirect the huntingtin protein from accumulating in the wrong place within brain cells, which could potentially translate to a therapy for Huntington's Disease (HD).
As she herded her two young sons into bed one evening late last December, Laura Devitt flipped through her phone to check on the routine blood tests that had been performed as part of her annual physical. She logged onto the patient portal link on her electronic medical record, scanned the results and felt her stomach clench with fear.
› Verified 2 days ago
| Entity Name | Oregon Healthcare Resources Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982907572 PECOS PAC ID: 4486835477 Enrollment ID: O20110223001220 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.
McMaster scientists are very close to defining small molecule drugs that should be able to redirect the huntingtin protein from accumulating in the wrong place within brain cells, which could potentially translate to a therapy for Huntington's Disease (HD).
As she herded her two young sons into bed one evening late last December, Laura Devitt flipped through her phone to check on the routine blood tests that had been performed as part of her annual physical. She logged onto the patient portal link on her electronic medical record, scanned the results and felt her stomach clench with fear.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Susan L Urben, MD Po Box 1648, Eugene, OR 97440-1648 Ph: (541) 334-3370 | Susan L Urben, MD 330 S Garden Way, Ste 300, Eugene, OR 97401-8176 Ph: (541) 334-3370 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy.
A Ludwig Cancer Research study explains why a particular mutation in the epidermal growth factor receptor, a cell surface protein, results in more aggressive tumors and poorer overall survival of patients diagnosed with the brain cancer glioblastoma multiforme.
McMaster scientists are very close to defining small molecule drugs that should be able to redirect the huntingtin protein from accumulating in the wrong place within brain cells, which could potentially translate to a therapy for Huntington's Disease (HD).
As she herded her two young sons into bed one evening late last December, Laura Devitt flipped through her phone to check on the routine blood tests that had been performed as part of her annual physical. She logged onto the patient portal link on her electronic medical record, scanned the results and felt her stomach clench with fear.
› Verified 2 days ago
Prashant P Vivek, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 330 S Garden Way, Suite 300, Eugene, OR 97401 Phone: 541-334-3370 Fax: 541-334-3372 | |
William David Tom, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 330 S Garden Way, Suite 300, Eugene, OR 97401 Phone: 541-334-3370 Fax: 541-334-3372 | |
Dr. Kenneth Albert Springate, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 2095 Broadview St, Eugene, OR 97405 Phone: 541-342-3140 | |
Dr. Grace X. Tan, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 1200 Hilyard St Ste 620, Eugene, OR 97401 Phone: 458-205-6500 Fax: 458-205-6453 | |
Dr. George Wallace Johansen, M.M. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 1200 Hilyard St, Suite S-200, Eugene, OR 97401 Phone: 541-685-1755 | |
Nathan P Christensen, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1200 Hilyard St, Suite 620, Eugene, OR 97401 Phone: 458-205-6500 |